EP Patent

EP2437732B1 — Combination of dopamine agonists plus first phase insulin secretagouges for the treatment of metabolic disorders

Assigned to Veroscience LLC · Expires 2018-05-09 · 8y expired

What this patent protects

Patent listed against bromocriptine-mesylate.

Drugs covered by this patent

bromocriptine-mesylate (BROMOCRIPTINE MESYLATE)

Patent Metadata

Patent number: EP2437732B1
Jurisdiction: EP
Classification: —
Expires: 2018-05-09
Drug substance claim: No
Drug product claim: No
Assignee: Veroscience LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.